MITF deficiency and oncogenic GNAQ each promote proliferation programs in zebrafish melanocyte lineage cells
Name
Pigment Cell Melanoma Res - 2022 - Phelps - MITF deficiency and oncogenic GNAQ each promote proliferation programs in.pdf
Description
Published version
Size
4.15 MB
Format
Adobe PDF
Checksum (MD5)
3976666345c21514c9b0c8d38bd08000
Author(s)
Phelps, Grace B
Amsterdam, Adam
Hagen, Hannah R
García, Nicole Zambrana
Lees, Jacqueline A
Date Issued
September 2022
Journal
Pigment Cell & Melanoma Research
Publisher
Wiley
Citation
Phelps, G. B., Amsterdam, A., Hagen, H. R., García, N. Z., & Lees, J. A. (2022). MITF deficiency and oncogenic GNAQ each promote proliferation programs in zebrafish melanocyte lineage cells. Pigment Cell & Melanoma Research, 35, 539–547
Version
Final published version
Abstract
Uveal melanoma (UM) is the most common primary malignancy of the adult eye but lacks any FDA-approved therapy for the deadly metastatic disease. Thus, there is a great need to dissect the driving mechanisms for UM and develop strategies to evaluate potential therapeutics. Using an autochthonous zebrafish model, we previously identified MITF, the master melanocyte transcription factor, as a tumor suppressor in GNAQQ209L -driven UM. Here, we show that zebrafish mitfa-deficient GNAQQ209L -driven tumors significantly up-regulate neural crest markers, and that higher expression of a melanoma-associated neural crest signature correlates with poor UM patient survival. We further determined how the mitfa-null state, as well as expression of GNAQQ209L , YAPS127A;S381A , or BRAFV600E oncogenes, impacts melanocyte lineage cells before they acquire the transformed state. Specifically, examination 5 days post-fertilization showed that mitfa-deficiency is sufficient to up-regulate pigment progenitor and neural crest markers, while GNAQQ209L expression promotes a proliferative phenotype that is further enhanced by YAPS127A;S381A co-expression. Finally, we show that this oncogene-induced proliferative phenotype can be used to screen chemical inhibitors for their efficacy against the UM pathway. Overall, this study establishes that a neural crest signature correlates with poor UM survival, and describes an in vivo assay for preclinical trials of potential UM therapeutics.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution NonCommercial License 4.0
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1111/pcmr.13057
